In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.
The IAS-led Global HIV Vaccine Enterprise welcomes new results from the AMP proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections.
HIV vaccine highlights and spotlights – To help attendees manage their time and navigate a busy programme, the Enterprise has developed an HIV vaccine R&D roadmap which covers active immunization and passive immunization with broadly neutralizing antibodies (bNAbs), especially VRC01.
VIDEO – Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’
The video recording of the Global HIV Vaccine Enterprise and IAVI webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention is now available online.
The Global HIV Vaccine Enterprise at the International AIDS Society and IAVI are pleased to invite you to join a webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention:
“Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’’
The IAS hosted Global HIV Vaccine Enterprise welcomes interim results showing effectiveness of long-acting injectable PrEP. New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill in a trial of women at increased risk of HIV acquisition.
NOW VIRTUAL ! This scientific and technical workshop aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, held in November 2018 in Seattle by the Fred Hutch and the NIAID. Participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learned for current HIV prevention designs.
With over 600 virtual sessions and events, AIDS 2020: Virtual will enable delegates to access and engage with the latest HIV science, advocacy and knowledge traditionally presented at the conference, while offering a range of new features made possible by the new virtual format. Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Download the HIV vaccine, and vaccine research roadmap.
SARS-CoV-2, the virus that causes COVID-19, has taken the world by surprise, just as HIV did in the 1980’s. However, unlike HIV, the world has come together and shown that a coordinated, global response to a pandemic is possible in record time. Many aspects of this response, including the search for a vaccine, have built upon technologies and lessons learned from recent epidemics, including HIV.
Every year, World Immunization Week is celebrated during the last week of April with the aim of promoting the use of vaccines to protect people against infectious diseases. Although much progress has been made to develop vaccines, an HIV vaccine remains elusive. In this post we revisit one of the most promising HIV prevention vaccine studies that was prematurely halted due to lack of efficacy and highlight its critical role in informing HIV vaccine development.
